(688382)"INVENTISBIO CO., LIMITED"Announcement on Convening the Q3 2026 Performance Briefing
Filed with SSE · Stock code 688382 · · 3 pages · Chinese
Summary by 6ix AI
The meeting is scheduled to take place online at the Shanghai Stock Exchange Roadshow Center. Investors can submit questions in advance and will receive answers during the briefing. The announcement includes details about the meeting time, location, and participation methods.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/688382inventisbio-co-limitedannouncement-on-convening-the-q3-2026-performance-briefing
Story so far
- (688382)"INVENTISBIO CO., LIMITED"Announcement on the Phase III Clinical Study of Nomelcitinib (D-2570) for the Treatment of Moderate-to-Severe Plaque Psoriasis Achieving the Primary Endpoint
- (688382)"INVENTISBIO CO., LIMITED"Announcement on Vesting Results for the Third Vesting Period of the Reserved Grant under the 2022 Restricted Share Incentive Plan and Listing of Shares
- Announcement on Convening the 2026 Semi-annual Performance Briefing
Earlier from InventisBio
- (688382)"INVENTISBIO CO., LIMITED"Announcement on the Phase III Clinical Study of Nomelcitinib (D-2570) for the Treatment of Moderate-to-Severe Plaque Psoriasis Achieving the Primary Endpoint
- (688382)"INVENTISBIO CO., LIMITED"Report for Q3 2026
- (688382)"INVENTISBIO CO., LIMITED"Announcement on Vesting Results for the Third Vesting Period of the Reserved Grant under the 2022 Restricted Share Incentive Plan and Listing of Shares
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on the Satisfaction of Vesting Conditions for the 3rd Vesting Period of the Reserved Grant under the 2022 Restricted Share Incentive Plan
Follow InventisBio into a list and get an email when it puts out news.
Follow InventisBio